More on BioScrip (BIOS): Q4 easily beats across the board on a 14% rise in total sales. Gross profit from continuing operations was 33.4% of revenue, as compared to 37.0% in the prior year period. For FY13, the company sees revenues in a range of $830M to $865M and is initially targeting 2013 Adjusted EBITDA of $67M to $73M. Analysts are forecasting revenues of $769.9M and EBITDA of $67.8M. Shares +8.3% AH.